Blog
RSS FeedPosted by Michael Wonder on 15 Sep 2020
Rep Grothman introduces bill for automatic insulin biosimilar interchangeablity
15 September 2020 - Representative Glenn Grothman, (R-Wisconsin), says interchangeability for insulins makes sense based on the savings potential and safety ...
Posted by Michael Wonder on 15 Sep 2020
NIH 'very concerned' about serious side effect in AstraZeneca coronavirus vaccine trial
15 September 2020 - The FDA is weighing whether to follow British regulators in resuming a coronavirus vaccine trial that ...
Posted by Michael Wonder on 15 Sep 2020
Apellis announces submission of pegcetacoplan marketing applications to FDA and EMA for patients with PNH
15 September 2020 - -- Apellis Pharmaceuticals today announced that the company has submitted a new drug application to the ...
Posted by Michael Wonder on 15 Sep 2020
Plus Therapeutics receives fast track designation from FDA for its novel glioblastoma treatment
15 September 2020 - Plus Therapeutics today announced that the U.S. FDA has granted the Company fast track designation for its ...
Posted by Michael Wonder on 15 Sep 2020
US FDA grants fast track designation to Jardiance (empagliflozin) to improve outcomes following a heart attack
15 September 2020 - This fast track designation for empagliflozin emphasises the urgent need for potential treatments that may improve outcomes ...
Posted by Michael Wonder on 15 Sep 2020
Ziopharm Oncology granted rare paediatric disease designation for controlled IL-12 for the treatment of DIPG
14 September 2020 - -- Ziopharm Oncology today announced that the U.S. FDA has granted rare paediatric disease designation to ...
Posted by Michael Wonder on 14 Sep 2020
Vaccine makers keep safety details quiet, alarming scientists
13 September 2020 - Researchers say drug companies need to be more open about how vaccine trials are run to reassure ...
Posted by Michael Wonder on 14 Sep 2020
ESSA Pharma announces fast track designation granted by the FDA to EPI-7386 for the treatment of metastatic castration-resistant prostate cancer
14 September 2020 - ESSA Pharma today announced that the US FDA granted fast track designation to EPI-7386, its oral ...
Posted by Michael Wonder on 14 Sep 2020
Sol-Gel Technologies announces FDA acceptance for filing of new drug application for Epsolay for the treatment of inflammatory lesions of rosacea
10 September 2020 - Potential to be first FDA-approved single-agent benzoyl peroxide prescription drug product. ...
Posted by Michael Wonder on 14 Sep 2020
Mallinckrodt receives a complete response letter from the U.S. FDA for terlipressin for the treatment of hepatorenal syndrome type 1
14 September 2020 - Company remains committed to working with FDA toward an approval for this important potential therapy. ...
Posted by Michael Wonder on 14 Sep 2020
FDA grants Dupixent (dupilumab) breakthrough therapy designation for eosinophilic oesophagitis
14 September 2020 - There are currently no FDA approved treatments for this chronic type 2 inflammatory disease that damages the ...
Posted by Michael Wonder on 14 Sep 2020
Pfizer CEO 'preparing' for likelihood of vaccine approval before end of year
13 September 2020 - Pharmaceutical company Pfizer is preparing for the likelihood of regulators approving the coronavirus vaccine the company ...
Posted by Michael Wonder on 14 Sep 2020
Trump pressed for plasma therapy. Officials worry, is an unvetted vaccine next?
12 September 2020 - New details of how the president has demanded faster action from health agencies help explain the intensifying ...
Posted by Michael Wonder on 11 Sep 2020
Junshi Biosciences receives FDA breakthrough therapy designation for toripalimab for the treatment of nasopharyngeal carcinoma
10 September 2020 - Junshi Biosciences announced today that the US FDA has recently granted breakthrough therapy designation to toripalimab for ...
Posted by Michael Wonder on 10 Sep 2020
Terns Pharmaceuticals receives fast track designation for TERN-201 as a treatment for NASH
10 September 2020 - Clinical trial of semicarbazide-sensitive amine oxidase inhibitor TERN-201 in NASH patients planned for early 2021. ...